Core Insights - The theme for this year's National Love Your Teeth Day emphasizes the importance of oral health as a component of overall health, with a focus on reducing sugar intake and promoting dental health [1] Industry Overview - Approximately 66% of listed dental companies reported revenues exceeding 100 million yuan, with many achieving profitability through cost reduction and operational restructuring [1] - The highest revenue in the dental medical service sector was reported by Tongce Medical at approximately 1.345 billion yuan, while the lowest was by Zhongzai Dental at around 23.78 million yuan [1] Company Performance - Tongce Medical achieved a revenue of 1.448 billion yuan in the reporting period, marking a year-on-year increase of 2.68%, with a net profit of 321 million yuan, up 3.67% [2] - The company operates 89 medical institutions and has 4,452 professional medical staff, with a dental outpatient volume of 1.7322 million, reflecting a growth of 1.21% [2] - Revenue from various business segments for Tongce Medical includes: implants (255 million yuan), orthodontics (229 million yuan), pediatrics (236 million yuan), restorations (230 million yuan), and comprehensive services (394 million yuan) [2] Market Dynamics - The growth in the oral medical service market is driven by three main factors: aging population leading to increased demand for dental restoration, high prevalence of orthodontic issues among youth, and rising consumer demand for aesthetic dental solutions [2] - Tongce Medical's revenue from Zhejiang province accounted for 91.36% of total revenue, indicating a strong regional dependency, with plans to expand into other markets through acquisitions [3] Competitive Landscape - The number of dental medical institutions is projected to reach 144,500 by 2025, with a compound annual growth rate of 10.4%, indicating increasing competition and potential industry consolidation [4] - Other dental service companies with revenues exceeding 100 million yuan include Dazhong Dental (186 million yuan), Ke'en Dental (170 million yuan), and Yaboshi (804 million yuan) [4] Technological Advancements - The application of AI technology in the dental industry is advancing, with companies like Meiya Optical launching innovative products such as the first oral imaging smart device [5] - The oral care market is identified as a significant growth area, with companies like Yunnan Baiyao and Dengkang Dental showing substantial revenue growth [5]

Group 1 - Company Tongce Medical (SH 600763) announced on September 16 that its controlling shareholder, Baoqun Industrial, has pledged 2.25 million shares, accounting for 1.48% of Baoqun's total holdings in the company and 0.50% of the company's total shares [1] - Baoqun Industrial also released 2.87 million shares from pledge, which represents 1.89% of its holdings and 0.64% of the company's total shares [1] - The total number of pledged shares by Baoqun Industrial is approximately 98.48 million, making up 64.96% of its holdings and 22.02% of the company's total shares [1] Group 2 - As of the report date, Tongce Medical's market capitalization is 21 billion yuan [1] - For the first half of 2025, the revenue composition of Tongce Medical is as follows: medical services account for 92.84%, product sales for 4.06%, construction engineering for 2.72%, and others for 0.38% [1]

证券简称：通策医疗 证券代码：600763 编号：临 2025-027 通策医疗股份有限公司 关于控股股东部分股票质押及解除质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏， 并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示: 杭州宝群实业集团有限公司（以下简称"宝群实业"）持有通策医疗股份有 限公司（以下简称"公司"）股份总数 151,589,199 股，占总股本的 33.89%；本次质 押股份数为 2,250,000 股，占宝群实业所持有本公司股份数 1.48%，占本公司总股份 数的 0.50%；同时办理解除质押股份数为 2,871,219 股，占宝群实业所持有本公司股 份数的 1.89%，占本公司总股份数的 0.64%。宝群实业质押股份总数为 98,476,672 股， 占宝群实业所持有本公司股份数的 64.96%，占本公司总股份数的 22.02%；宝群实业 的一致行动人吕建明先生持股总数 2,091,088 股，占总股本的 0.47%，并无质押；宝 群实业已质押股份数占宝群实业及其一致行动人所持有本公司股份数的 64.08%，占本 公司总股 ...

Group 1 - The stock price of Tongce Medical (600763) closed at 47.36 yuan, up 1.96% from last week’s 46.45 yuan, with a market cap of 21.157 billion yuan [1] - The highest intraday price reached 48.35 yuan on September 8, while the lowest was 45.6 yuan on September 11 [1] - Tongce Medical ranks 8th out of 50 in the medical services sector by market capitalization and 891st out of 5153 in the A-share market [1] Group 2 - The controlling shareholder, Baoqun Industrial, holds 151,589,199 shares, accounting for 33.89% of the total share capital [2] - Baoqun Industrial pledged 8,410,000 shares, which is 5.55% of its holdings and 1.88% of the total share capital, while simultaneously unpledging 8,403,570 shares [2][3] - The total pledged shares by Baoqun Industrial amount to 99,097,891 shares, representing 65.37% of its holdings and 22.16% of the total share capital, with the pledged financing intended for off-system medical project funding [2][3]

Trading Information Summary - On September 11, 2025, Tongce Medical (600763) closed at 47.78 yuan, up 1.64%, with a turnover rate of 3.49% and a trading volume of 156,200 shares, amounting to a transaction value of 738 million yuan [1] - On the same day, the net inflow of main funds was 28.76 million yuan, accounting for 3.9% of the total transaction value [3] Company Announcement Summary - Tongce Medical announced that its controlling shareholder, Baoqun Industrial, holds 151,589,199 shares, representing 33.89% of the total share capital. This time, 8,410,000 shares were pledged, accounting for 5.55% of its holdings and 1.88% of the company's total share capital. Simultaneously, 8,403,570 shares were released from pledge, also accounting for 5.54% of its holdings and 1.88% of the company's total share capital [1] - Baoqun Industrial has cumulatively pledged 99,097,891 shares, which is 65.37% of its holdings and 22.16% of the company's total share capital. Its concerted actor, Lv Jianming, holds 2,091,088 shares with no pledges [1] - The total pledged shares by Baoqun Industrial and its concerted actor account for 64.48% of their combined holdings and 22.16% of the company's total share capital. The pledged financing is intended for off-system medical project funding needs. Baoqun Industrial has good creditworthiness and repayment capability, indicating that the pledge risk is controllable and will not affect the company's main business and actual control [1]

证券简称：通策医疗 证券代码：600763 编号：临 2025-026 通策医疗股份有限公司 重要内容提示: 杭州宝群实业集团有限公司（以下简称"宝群实业"）持有通策医疗股份有 限公司（以下简称"公司"）股份总数 151,589,199 股，占总股本的 33.89%；本次质 押股份数为 8,410,000 股，占宝群实业所持有本公司股份数 5.55%，占本公司总股份 数的 1.88%；同时办理解除质押股份数为 8,403,570 股，占宝群实业所持有本公司股 份数的 5.54%，占本公司总股份数的 1.88%。宝群实业质押股份总数为 99,097,891 股， 占宝群实业所持有本公司股份数的 65.37%，占本公司总股份数的 22.16%；宝群实业 的一致行动人吕建明先生持股总数 2,091,088 股，占总股本的 0.47%，并无质押；宝 群实业已质押股份数占宝群实业及其一致行动人所持有本公司股份数的 64.48%，占本 公司总股份数的 22.16%。 一、上市公司股份质押情况 2025 年 9 月 11 日接到控股股东宝群实业股票质押及解除质押交易通知，具体事 项如下。 | 股东 | 是否为 | 本次质 ...

Investment Rating - The industry investment rating is maintained as "Buy" [1] Core Insights - The overall performance of the industry has shown significant improvement, with a notable recovery in revenue and profit margins [3][14] - Private medical services are under short-term pressure, while the CXO sector continues to perform well, particularly in ADC and CDMO related companies [4][6] - The core contradiction in the industry has shifted from "insufficient effective supply" to a new phase of "medical insurance cost control" due to increasing demand from an aging population [5][6] Summary by Sections Overall Industry Performance - The pharmaceutical manufacturing industry reported a cumulative revenue of 1.23 trillion yuan in the first half of 2025, a year-on-year decline of 1.20%, but the decline is narrowing month by month [5][14] - The medical service sector achieved a revenue of 883.6 billion yuan in 2025H1, with a year-on-year growth of 3.8% and a net profit growth of 43.0% [29] Private Medical Services and CXO Sector - Private medical services are experiencing short-term pressure, with the ophthalmology sector showing relatively strong performance [4][39] - The CXO sector's performance continues to improve, with significant growth in ADC and CDMO related companies [4][6] IVD and ICL Performance - The IVD sector is under pressure due to medical insurance cost control and centralized procurement policies, impacting short-term performance [5][6] - The ICL sector is facing a downward trend, with increased competition and pressure from medical insurance cost control [8][6] Investment Recommendations - The report suggests focusing on high-growth areas such as ADC CDMO and the weight-loss drug supply chain, as well as sectors with expected improvements like ophthalmology and dental services [6][29]

Investment Rating - The investment rating for the company is "Buy" (maintained) [7] Core Views - The company's performance is steadily growing, driven by its orthodontic business, with a revenue of 1.448 billion yuan in H1 2025, representing a year-on-year increase of 2.68% [5][11] - The gross margin remains stable, with a gross margin of 40.75% in H1 2025, showing a slight decrease of 0.08 percentage points year-on-year [12] - The company is expanding its operations through a "regional general hospital + branch" structure, enhancing its presence in the province and accelerating nationwide coverage through acquisitions and light asset franchises [14] Financial Performance - In H1 2025, the company achieved a net profit of 321 million yuan, up 3.67% year-on-year, with Q2 2025 net profit at 137 million yuan, an increase of 0.44% year-on-year [5][11] - Revenue breakdown by segment in H1 2025: - Implant business: 255 million yuan (18.9% of total revenue, +0.02% year-on-year) - Orthodontics: 229 million yuan (17.0% of total revenue, +7.75% year-on-year) - Pediatrics: 236 million yuan (17.6% of total revenue, -1.48% year-on-year) - Restoration: 230 million yuan (17.1% of total revenue, +3.59% year-on-year) [13] Future Projections - Revenue projections for 2025-2027 are as follows: - 2025: 3.029 billion yuan (+5.40% year-on-year) - 2026: 3.336 billion yuan (+10.13% year-on-year) - 2027: 3.737 billion yuan (+12.01% year-on-year) [15] - Net profit projections for the same period are: - 2025: 519 million yuan (+3.55% year-on-year) - 2026: 585 million yuan (+12.61% year-on-year) - 2027: 675 million yuan (+15.50% year-on-year) [15] Valuation Metrics - The company’s earnings per share (EPS) are projected to be: - 2025: 1.16 yuan - 2026: 1.31 yuan - 2027: 1.51 yuan [15] - Price-to-earnings (P/E) ratio is expected to decrease from 42.1 in 2023 to 31.2 in 2027 [16]

Core Viewpoint - Tongce Medical (600763) experienced a decline in stock price, closing at 47.12 yuan on September 9, 2025, with a drop of 1.36% [1] Financial Performance - For the first half of 2025, Tongce Medical reported a main revenue of 1.448 billion yuan, an increase of 2.68% year-on-year [3] - The net profit attributable to shareholders was 321 million yuan, up 3.67% year-on-year [3] - The second quarter of 2025 saw a single-quarter main revenue of 704 million yuan, a slight increase of 0.24% year-on-year [3] - The company’s gross profit margin stood at 40.75%, while the net profit margin was 26.26% [3] Market Activity - On September 9, 2025, the net outflow of main funds was 36.31 million yuan, accounting for 8.84% of the total transaction amount [1] - Retail investors showed a net inflow of 27.30 million yuan, representing 6.65% of the total transaction amount [1] - Over the past five days, the stock has seen fluctuating fund flows, with notable net inflows and outflows from different investor categories [2] Industry Comparison - Tongce Medical's total market value is 21.076 billion yuan, slightly above the industry average of 20.997 billion yuan [3] - The company ranks 5th in the industry based on price-to-earnings ratio (32.81) and 3rd based on net profit margin (26.26%) [3] - The company has a debt ratio of 27.51% and reported investment income of 27.09 million yuan [3] Analyst Ratings - In the last 90 days, 7 institutions rated the stock, with 5 buy ratings and 2 hold ratings [4] - The average target price set by institutions over the past 90 days is 50.19 yuan [4]

Investment Rating - The report maintains an "Accumulate" rating for the company [6][13]. Core Views - The company has entered a performance contribution phase with its local branch network, while exploring new expansion models through acquisitions and franchises outside the province. The impact of the dental implant procurement has passed, and the orthodontic business is stabilizing and recovering [2][13]. - The company achieved a revenue of 1.448 billion yuan in the first half of 2025, representing a year-on-year increase of 2.68%, and a net profit attributable to the parent company of 321 million yuan, up 3.67% year-on-year [13]. - The report adjusts the earnings per share (EPS) forecast for 2025-2027 to 1.20, 1.29, and 1.41 yuan, respectively, and sets a target price of 48.48 yuan based on a price-to-earnings (PE) ratio of 40.5X for 2025 [13]. Financial Summary - Total revenue is projected to grow from 2.847 billion yuan in 2023 to 3.363 billion yuan in 2027, with a compound annual growth rate (CAGR) of approximately 6.2% [4][14]. - Net profit attributable to the parent company is expected to increase from 500 million yuan in 2023 to 629 million yuan in 2027, reflecting a CAGR of about 8.8% [4][14]. - The company operates 89 medical institutions with 4,452 professional medical personnel and over 3100 dental treatment units, serving 1.7322 million outpatient visits in the first half of 2025 [13]. Business Performance - The revenue from the company's various business segments in the first half of 2025 includes: dental implants (255 million yuan), orthodontics (229 million yuan), pediatrics (236 million yuan), restoration (230 million yuan), and comprehensive services (394 million yuan), with year-on-year growth rates of 0.02%, 7.75%, -1.48%, 3.59%, and 2.44%, respectively [13]. - The company has established five regional groups in Zhejiang Province, enhancing its penetration and service capabilities through a "regional general hospital + branch" structure [13]. Technology and Innovation - The company utilizes AI technology through its self-developed MindHub platform, which supports clinical diagnosis, patient services, and operational management, enhancing efficiency and aiding in further expansion [13].